International Journal of Molecular Sciences the Potential of Targeting Ribosome Biogenesis in High-grade Serous Ovarian Cancer
暂无分享,去创建一个
R. Pearson | R. Hannan | K. Hannan | E. Sanij | Keefe T. Chan | Daniel Frank | Jinbae Son | Shunfei Yan | K. T. Chan | Kwong-Kwok Wong
[1] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[2] K. Khanna,et al. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling , 2016, Oncotarget.
[3] R. Pearson,et al. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer , 2016, Clinical Cancer Research.
[4] Y. Drew,et al. Homologous recombination deficiency and ovarian cancer. , 2016, European journal of cancer.
[5] K. Wiman,et al. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer , 2016, Journal of Ovarian Research.
[6] G. Narayanan,et al. Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments , 2016, Ecancermedicalscience.
[7] L. Montanaro,et al. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate , 2016, Oncogene.
[8] G. Shapiro,et al. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.
[9] V. Beral,et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.
[10] P. Brown,et al. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells , 2015, Oncotarget.
[11] Kylie L. Gorringe,et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors , 2015, Genome Medicine.
[12] Jacobus Pfisterer,et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial , 2015, The Lancet. Oncology.
[13] R. Pearson,et al. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. , 2015, Biochimica et biophysica acta.
[14] G. Thomas,et al. A liaison between mTOR signaling, ribosome biogenesis and cancer. , 2015, Biochimica et biophysica acta.
[15] P. Thaker,et al. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. , 2015, Gynecologic oncology.
[16] P. Brown,et al. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis , 2015, Oncotarget.
[17] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[18] G. McArthur,et al. A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM). , 2015 .
[19] C. Scott,et al. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Mabuchi,et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. , 2015, Gynecologic oncology.
[21] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[22] A. Leary,et al. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges , 2015, Chinese journal of cancer.
[23] R. Hannan,et al. Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease , 2014, Cell & Bioscience.
[24] J. Ledermann,et al. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential , 2014, Therapeutic advances in medical oncology.
[25] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[26] R. Pearson,et al. Targeting the nucleolus for cancer intervention. , 2014, Biochimica et biophysica acta.
[27] A. Reuss,et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Hannan,et al. Targeting RNA polymerase I to treat MYC-driven cancer , 2014, Oncogene.
[29] C. Rubbi,et al. Nucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy , 2014, Cellular and Molecular Life Sciences.
[30] M. Burgess,et al. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different , 2014, Front. Oncol..
[31] C. Rommel,et al. PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.
[32] C. Bieberich,et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. , 2014, Cancer cell.
[33] D. Bowtell,et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. , 2013, European journal of cancer.
[34] R. Hannan,et al. The nucleolus: an emerging target for cancer therapy. , 2013, Trends in molecular medicine.
[35] C. Landen,et al. The role of the fallopian tube in the origin of ovarian cancer. , 2013, American journal of obstetrics and gynecology.
[36] R. Pearson,et al. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ‐Myc B‐cell lymphoma in vivo , 2013, The FEBS journal.
[37] D. Eick,et al. Functional ribosome biogenesis is a prerequisite for p53 destabilization: impact of chemotherapy on nucleolar functions and RNA metabolism , 2013, Biological chemistry.
[38] Ling-Zhi Wang,et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer , 2013, EMBO molecular medicine.
[39] R. Pearson,et al. Dysregulation of the basal RNA polymerase transcription apparatus in cancer , 2013, Nature Reviews Cancer.
[40] I. Willis,et al. Regulation of pol III transcription by nutrient and stress signaling pathways. , 2013, Biochimica et biophysica acta.
[41] R. Pearson,et al. Dysregulation of RNA polymerase I transcription during disease. , 2013, Biochimica et biophysica acta.
[42] M. Morgan,et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. , 2013, The Lancet. Oncology.
[43] D. Ruggero. Revisiting the Nucleolus: From Marker to Dynamic Integrator of Cancer Signaling , 2012, Science Signaling.
[44] J. George,et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Carleen Cullinane,et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.
[46] H. Hurwitz,et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors , 2012, Cancer Chemotherapy and Pharmacology.
[47] G. Thomas,et al. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. , 2012, Genes & development.
[48] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[49] Jacobus Pfisterer,et al. A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.
[50] D. Spandidos,et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). , 2011, International journal of oncology.
[51] J. Brenton,et al. Evolution of platinum resistance in high-grade serous ovarian cancer. , 2011, The Lancet. Oncology.
[52] S. Mok,et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. , 2011, Gynecologic oncology.
[53] Ricky W Johnstone,et al. AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer , 2011, Science Signaling.
[54] I. Shih,et al. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.
[55] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[56] Rodney J Hicks,et al. In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer , 2011, Molecular Cancer Therapeutics.
[57] S. Pyndiah,et al. c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance , 2011, Science Signaling.
[58] R. Hannan,et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.
[59] R. Pearson,et al. Signaling to the ribosome in cancer—It is more than just mTORC1 , 2011, IUBMB life.
[60] G. McArthur,et al. c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation , 2010, Nucleic acids research.
[61] David D. L. Bowtell,et al. The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.
[62] F. Boisvert,et al. The Nucleolus under Stress , 2010, Molecular Cell.
[63] Maria P. Pavlou,et al. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer , 2010, Nature Reviews Cancer.
[64] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[65] D. Felsher,et al. MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.
[66] P. Hainaut,et al. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis , 2010, Oncogene.
[67] E. Kremmer,et al. Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels* , 2010, The Journal of Biological Chemistry.
[68] I. Grummt,et al. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. , 2010, Annual review of pharmacology and toxicology.
[69] D. Ruggero. The role of Myc-induced protein synthesis in cancer. , 2009, Cancer research.
[70] Yanping Zhang,et al. Signaling to p53: ribosomal proteins find their way. , 2009, Cancer cell.
[71] I. Shih,et al. Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.
[72] Robert C. Bast,et al. The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.
[73] Jan Bergman,et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. , 2009, Cancer cell.
[74] V. Velculescu,et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.
[75] R. Memmott,et al. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. , 2009, Cellular signalling.
[76] A. Wright,et al. c-Myc induces changes in higher order rDNA structure on stimulation of quiescent cells , 2009, Oncogene.
[77] R. Penson,et al. Ovarian stromal and germ cell tumors. , 2009, Seminars in oncology.
[78] Matthew Burnell,et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) , 2009, Journal of Family Planning and Reproductive Health Care.
[79] Timothy A. Yap,et al. Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.
[80] E. Raymond,et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours , 2009, British Journal of Cancer.
[81] K. Vousden,et al. Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway , 2008, Oncogene.
[82] Pier Paolo Pandolfi,et al. The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.
[83] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[84] B. Karlan,et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.
[85] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.
[86] Anil K Sood,et al. Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] K. Vousden,et al. Coping with stress: multiple ways to activate p53 , 2007, Oncogene.
[88] J. Krischer,et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.
[89] J. Testa,et al. Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.
[90] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[91] Carla Grandori,et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I , 2005, Nature Cell Biology.
[92] Lars-Gunnar Larsson,et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription , 2005, Nature Cell Biology.
[93] R. Pearson,et al. MAD1 and c‐MYC regulate UBF and rDNA transcription during granulocyte differentiation , 2004, The EMBO journal.
[94] Andrew K Godwin,et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth , 2004, Oncogene.
[95] E. Schmidt. The role of c-myc in regulation of translation initiation , 2004, Oncogene.
[96] M. Jordan,et al. Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.
[97] Brigitte M. Ronnett,et al. The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[98] Z. Siddik,et al. Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.
[99] Hys Ngan,et al. Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[100] R. Agarwal,et al. Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.
[101] Ed Hurt,et al. Pre-ribosomes on the road from the nucleolus to the cytoplasm. , 2003, Trends in cell biology.
[102] P. Pandolfi,et al. Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.
[103] I. Grummt,et al. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. , 2003, Molecular cell.
[104] Mef Nilbert,et al. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis , 2002, Cancer.
[105] D. Leary,et al. Regulation of ribosome biogenesis within the nucleolus , 2001, FEBS letters.
[106] R. Hannan,et al. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. , 2001, Molecular cell.
[107] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[108] D. Treré,et al. Nucleolar size indicates the rapidity of cell proliferation in cancer tissues , 2000, The Journal of pathology.
[109] M. Bookman,et al. Second-line treatment of ovarian cancer. , 2000, The oncologist.
[110] Emmett V Schmidt,et al. The role of c-myc in cellular growth control , 1999, Oncogene.
[111] L. Montanaro,et al. Nucleolar function and size in cancer cells. , 1998, The American journal of pathology.
[112] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.
[113] R. Pearson,et al. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. , 2016, Cancer discovery.
[114] J. Coward,et al. New perspectives on targeted therapy in ovarian cancer , 2015 .
[115] D. Gershenson. The life and times of low-grade serous carcinoma of the ovary. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[116] J. Thigpen. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .
[117] J. Dungan. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .
[118] E. Friedman,et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] I. Wierstra,et al. The c-myc promoter: still MysterY and challenge. , 2008, Advances in cancer research.
[120] Celia Quevedo,et al. Biochemical mechanisms of cisplatin cytotoxicity. , 2007, Anti-cancer agents in medicinal chemistry.
[121] T. Moss,et al. A housekeeper with power of attorney: the rRNA genes in ribosome biogenesis , 2006, Cellular and Molecular Life Sciences.
[122] P Maisonneuve,et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.